Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Peptide Vaccine with or without IL-2 in Metastatic Ocular Melanoma
NCT00020475Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Feb 2001
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of gp100:209-217, melan-a analog peptide in Ocular melanoma (OM), sponsored by National Cancer Institute. Started Feb 2001; status: completed.
02
Drugs
gp100:209-217melan-a analog peptide
03
Conditions
Ocular melanoma (OM)
Beyond the preview
Go deeper on NCT00020475.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00020475.